ROS-responsive Prussian blue nanoplatform for synergistic myocardial ischemia/reperfusion injury therapy via EGCG delivery and DJ-1 pathway regulation

Key Points

• Improved myocardial ischemia/reperfusion injury outcomes highlight the efficacy of the novel nanoplatform.
• The study demonstrated a significant reduction in injury markers through DJ-1 pathway regulation by the nanoplatform.
• Assessment using a ROS-responsive Prussian Blue nanoplatform facilitated effective EGCG delivery for cardiac protection.
• These findings may enable new therapeutic approaches for cardiac injury, but further clinical validation is needed.